Pfizer Working To Develop New Packaging For Migraine Drug Over Child Safety, Poisoning Concerns - Pfizer (NYSE:PFE)

Pfizer Inc PFE recalled prescription migraine drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets.
The tablets are in a non-child-resistant blister card packaged in a carton containing the product's name, dosage strength, NDC number, and expiration date.
The U.S. Consumer Product Safety Commission (CPSC) said the packaging of the products is not child resistant, posing a risk of poisoning if young children swallow the contents.
Pfizer said it is working on new child-proof packaging for its migraine drug acquired through Biohaven Pharmaceutical's $11.6 billion buyout in 2022.
As an interim measure, the company has instructed pharmacists to place the drug packet in a child-resistant vial before dispensing it to patients.
"Patients should rest assured that there are no quality or safety issues nor health risks when they take medicine as prescribed for its approved use," Reuters notes, citing the company's statement.
The orally disintegrating tablets are used for treating acute migraine and as a preventive treatment for episodic migraine in adults.
Recently, the FDA has approved Zavzpret (zavegepant), another Biohaven product, calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, for the acute treatment of migraine with or without aura in adults.
Price Action: PFE shares are down 0.02% at $40.35 during the premarket session on the last check Friday.
Photo via Wikimedia Commons